An oncolytic adenovirus carrying DCN (rAd.DCN) has previously been developed, demonstrating inhibitory effects on breast cancer [17], as well as inhibiting tumor growth and lung metastasis of breast cancer [16] and bone metastasis of prostate cancer [18] in mouse models. Here, DCN is linked to prostate cancer.